Phase 1 study investigating RG0401
Latest Information Update: 16 Jan 2025
Price :
$35 *
At a glance
- Drugs RG 0401 (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Therapeutic Use
- 16 Jan 2025 New trial record
- 09 Jan 2025 According to RheumaGen media release, the company is currently conducting RG0401 IND-enabling studies and plans to begin the Phase I clinical trial in 2026.
- 09 Jan 2025 According to RheumaGen media release, company announced the close of a $15 million Series A financing co-led by SPRIM Global Investments and William Taylor Nominees.The financing will support RheumaGen in completing a Phase I clinical trial of its lead program, RG0401, for treatment-resistant or refractory rheumatoid arthritis (RA).